Ashton A Shaffer1,2, Christine M Durand3,4. 1. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. 2. Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD. 3. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 4. Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
PURPOSE OF REVIEW: The prevalence of end-stage organ disease is increasing among HIV-infected (HIV+) individuals. Individuals with well-controlled HIV on antiretroviral therapy (ART), without active opportunistic infections or cancer, and with specified minimum CD4 cell counts are appropriate transplant candidates. Infectious disease clinicians can improve access to transplantation for these patients and optimize management pre- and post-transplant. RECENT FINDINGS: Clinical trials and registry-based studies demonstrate excellent outcomes for select HIV+ kidney and liver transplant recipients with similar patient and graft survival as HIV-uninfected patients. Elevated allograft rejection rates have been observed in HIV+ individuals; this may be related to a dysregulated immune system or drug interactions. Lymphocyte-depleting immunosuppression has been associated with lower rejection rates without increased infections using national registry data. Hepatitis C virus (HCV) coinfection has been associated with worse outcomes, however improvements are expected with direct-acting antivirals. SUMMARY: Solid organ transplantation should be considered for HIV+ individuals with end-stage organ disease. Infectious disease clinicians can optimize ART to avoid pharmacoenhancers, which interact with immunosuppression. The timing of HCV treatment (pre- or post-transplant) should be discussed with the transplant team. Finally, organs from HIV+ donors can now be considered for HIV+ transplant candidates, within research protocols.
PURPOSE OF REVIEW: The prevalence of end-stage organ disease is increasing among HIV-infected (HIV+) individuals. Individuals with well-controlled HIV on antiretroviral therapy (ART), without active opportunistic infections or cancer, and with specified minimum CD4 cell counts are appropriate transplant candidates. Infectious disease clinicians can improve access to transplantation for these patients and optimize management pre- and post-transplant. RECENT FINDINGS: Clinical trials and registry-based studies demonstrate excellent outcomes for select HIV+ kidney and liver transplant recipients with similar patient and graft survival as HIV-uninfected patients. Elevated allograft rejection rates have been observed in HIV+ individuals; this may be related to a dysregulated immune system or drug interactions. Lymphocyte-depleting immunosuppression has been associated with lower rejection rates without increased infections using national registry data. Hepatitis C virus (HCV) coinfection has been associated with worse outcomes, however improvements are expected with direct-acting antivirals. SUMMARY: Solid organ transplantation should be considered for HIV+ individuals with end-stage organ disease. Infectious disease clinicians can optimize ART to avoid pharmacoenhancers, which interact with immunosuppression. The timing of HCV treatment (pre- or post-transplant) should be discussed with the transplant team. Finally, organs from HIV+ donors can now be considered for HIV+ transplant candidates, within research protocols.
Entities:
Keywords:
HIV infection; end-stage liver disease; end-stage renal disease; immunosuppression; kidney transplant; liver transplant; solid organ transplantation
Authors: Zihao Wu; Steven J Bensinger; Jidong Zhang; Chuangqi Chen; Xueli Yuan; Xiaolun Huang; James F Markmann; Alireza Kassaee; Bruce R Rosengard; Wayne W Hancock; Mohamed H Sayegh; Laurence A Turka Journal: Nat Med Date: 2003-11-30 Impact factor: 53.440
Authors: Mohamed G Atta; Derek M Fine; Gregory D Kirk; Shruti H Mehta; Richard D Moore; Gregory M Lucas Journal: Clin Infect Dis Date: 2007-12-15 Impact factor: 9.079
Authors: Jayme E Locke; Shikha Mehta; Rhiannon D Reed; Paul MacLennan; Allan Massie; Anoma Nellore; Christine Durand; Dorry L Segev Journal: J Am Soc Nephrol Date: 2015-03-19 Impact factor: 10.121
Authors: Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren Journal: J Infect Dis Date: 2005-08-11 Impact factor: 5.226
Authors: Margaret V Ragni; Steven H Belle; KyungAh Im; Guy Neff; Michelle Roland; Peter Stock; Nigel Heaton; Abhi Humar; John F Fung Journal: J Infect Dis Date: 2003-11-12 Impact factor: 5.226
Authors: Tania S Bonny; Charles Kirby; Craig Martens; Rebecca Rose; Niraj Desai; Michael Seisa; Christos Petropoulos; Sander Florman; Rachel J Friedman-Moraco; Nicole A Turgeon; Diane Brown; Dorry L Segev; Christine M Durand; Aaron A R Tobian; Andrew D Redd Journal: Lancet HIV Date: 2020-07-27 Impact factor: 12.767
Authors: Brian J Boyarsky; Mary Grace Bowring; Ashton A Shaffer; Dorry L Segev; Christine M Durand Journal: Curr Opin Organ Transplant Date: 2019-08 Impact factor: 2.640
Authors: Christine M Durand; Wanying Zhang; Diane M Brown; Sile Yu; Niraj Desai; Andrew D Redd; Serena M Bagnasco; Fizza F Naqvi; Shanti Seaman; Brianna L Doby; Darin Ostrander; Mary Grace Bowring; Yolanda Eby; Reinaldo E Fernandez; Rachel Friedman-Moraco; Nicole Turgeon; Peter Stock; Peter Chin-Hong; Shikha Mehta; Valentina Stosor; Catherine B Small; Gaurav Gupta; Sapna A Mehta; Cameron R Wolfe; Jennifer Husson; Alexander Gilbert; Matthew Cooper; Oluwafisayo Adebiyi; Avinash Agarwal; Elmi Muller; Thomas C Quinn; Jonah Odim; Shirish Huprikar; Sander Florman; Allan B Massie; Aaron A R Tobian; Dorry L Segev Journal: Am J Transplant Date: 2020-08-08 Impact factor: 9.369